Search

Your search keyword '"Maakaron, Joseph"' showing total 396 results
Start Over Author "Maakaron, Joseph"
396 results on '"Maakaron, Joseph"'

1. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Author

Wang, Trent P., Ahn, Kwang W., Shadman, Mazyar, Kaur, Manmeet, Ahmed, Nausheen, Bacher, Ulrike, Cerny, Jan, Chen, Andy, Epperla, Narendranath, Frigault, Matthew, Grover, Natalie, Haverkos, Bradley, Hill, Brian, Hossain, Nasheed, Iqbal, Madiha, Jain, Tania, Krem, Maxwell M., Maakaron, Joseph, Modi, Dipenkumar, Alhaj Moustafa, Muhamad, Riedell, Peter, Savani, Bipin, Sica, R. Alejandro, Sureda, Anna, Wudhikarn, Kitsada, Herrera, Alex F., Sauter, Craig, Hamadani, Mehdi, and Jimenez Jimenez, Antonio

Published
2024
Full Text
View/download PDF

3. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

Author

Iqbal, Madiha, Jagadeesh, Deepa, Chavez, Julio, Khurana, Arushi, Rosenthal, Allison, Craver, Emily, Epperla, Narendranath, Li, Zhuo, Isufi, Iris, Awan, Farrukh T., Dholaria, Bhagirathbhai R., Maakaron, Joseph E., Sandoval-Sus, Jose D., Mishra, Rahul, Saha, Aditi, Annunzio, Kaitlin, Bhaskar, Shakthi T., Sumransub, Nuttavut, Fijalka, Andrew, Ivanov, Stanislav A., Lin, Yi, and Kharfan-Dabaja, Mohamed A.

Published
2024
Full Text
View/download PDF

6. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Genetics, Transplantation, Pediatric Research Initiative, Childhood Leukemia, Stem Cell Research, Cancer, Clinical Research, Pediatric Cancer, Rare Diseases, Pediatric, Stem Cell Research - Nonembryonic - Human, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Risk Assessment, Transplantation Conditioning, Transplantation, Homologous, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p

Published
2021

9. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Author

Scordo, Michael, Flynn, Jessica R., Gonen, Mithat, Devlin, Sean M., Parascondola, Allison, Tomas, Ana Alarcon, Shouval, Roni, Brower, Jamie, Porter, David L., Schuster, Stephen J., Bachanova, Veronika, Maakaron, Joseph, Maziarz, Richard T., Chen, Andy I., Nastoupil, Loretta J., McGuirk, Joseph P., Oluwole, Olalekan O., Ip, Andrew, Leslie, Lori A., Bishop, Michael R., Riedell, Peter A., and Perales, Miguel-Angel

Published
2023
Full Text
View/download PDF

15. Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

Author

Maakaron, Joseph E., Zhang, Mei-Jie, Chen, Karen, Abhyankar, Sunil, Bhatt, Vijaya Raj, Chhabra, Saurabh, El Jurdi, Najla, Farag, Sherif S., He, Fiona, Juckett, Mark, de Lima, Marcos, Majhail, Navneet, van der Poel, Marjolein, Saad, Ayman, Savani, Bipin, Ustun, Celalettin, Waller, Edmund K., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, and Weisdorf, Daniel

Published
2022
Full Text
View/download PDF

16. Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes

Author

Kapadia, Malika, Lehmann, Leslie, Auletta, Jeffery, Beatty, Lisa, Bhatt, Neel, Blacken, Robyn, Demmel, Kathy, Dodd, Therese, Desmond, Catherine, Fitch, Taylor, Flesch, Laura, Hartley, David, Huber, John, Ingraham, Hannah, Jakubowski, Rita, Klunk, Anna, Krupski, Christa, Kusnier, Katilyn, Liberio, Nicole, Maakaron, Joseph, Mueller, Mark, Myers, Kasiani C., Pai, Ahna, Parker, Loretta, Patel, Sagar, Phelan, Rachel, Polishchuk, Veronika, Sigmund, Audrey, Sper, Christine, Tarquini, Sarah, Juckett, Mark, Jaglowski, Samantha, Dandoy, Christopher, and Rotz, Seth

Published
2022
Full Text
View/download PDF

19. Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2022
Full Text
View/download PDF

22. Frailty is associated with low physical activity and poor sleep quality in patients undergoing myeloablative allogeneic hematopoietic cell transplantation: A Fitbit Pilot Study

Author

Libbert, Caryn R., primary, He, Fiona, additional, El Jurdi, Najla, additional, Fagrelius, Helen, additional, Juckett, Mark, additional, Maakaron, Joseph, additional, Juckett, William, additional, Evanoff, Nicholas, additional, Dengel, Donald R., additional, and Holtan, Shernan G., additional

Published
2024
Full Text
View/download PDF

24. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

Author

Jurdi, Najla El, Hoover, Alex, O'Leary, Daniel, Cao, Qing, Gupta, Ashish, Ebens, Christen, Maakaron, Joseph E., Betts, Brian C., Rashidi, Armin, Juckett, Mark B., Lund, Troy, Bachanova, Veronika, MacMillan, Margaret L, Miller, Jeffrey S., Orchard, Paul J., Wagner, John E., Vercellotti, Gregory, Weisdorf, Daniel J., Dusenbery, Kathryn, Terezakis, Stephanie, and Holtan, Shernan G.

Published
2023
Full Text
View/download PDF

25. Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease

Author

Holtan, Shernan G., Hoeschen, Andrea, Cao, Qing, Ustun, Celalettin, Betts, Brian C., Jurdi, Najla El, Maakaron, Joseph, Rashidi, Armin, Miller, Jeffrey S., Wagner, John E., Blazar, Bruce R., Jacobson, Pamala A., Panoskaltsis-Mortari, Angela, Weisdorf, Daniel J., and MacMillan, Margaret L.

Published
2023
Full Text
View/download PDF

26. Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation

Author

El Jurdi, Najla, Rogosheske, John, DeFor, Todd, Bejanyan, Nelli, Arora, Mukta, Bachanova, Veronika, Betts, Brian, He, Fiona, Holtan, Shernan, Janakiram, Murali, Larson, Samantha, Maakaron, Joseph, Rashidi, Armin, Warlick, Erica, Wagner, John E., Young, Jo-Anne H., Weisdorf, Daniel, and Brunstein, Claudio G.

Published
2020
Full Text
View/download PDF

29. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

Author

Holtan, Shernan Grace, primary, Walton, Kelly, additional, El Jurdi, Najla, additional, Maakaron, Joseph E., additional, Juckett, Mark, additional, Bachanova, Veronika, additional, Myers, Thomas J, additional, Paradiso, Linda J., additional, DeFor, Todd E, additional, Cao, Qing, additional, and Betts, Brian C., additional

Published
2024
Full Text
View/download PDF

30. The Prevalence and Impact of Pre-Transplant Frailty and Mental Distress on Outcomes in Hematopoietic Cell Transplantation

Author

Singh, Shivjot, primary, Cao, Qing, additional, Demorest, Connor, additional, He, Fiona, additional, Holtan, Shernan Grace, additional, Maakaron, Joseph E., additional, O'Leary, Daniel, additional, Kao, Roy, additional, Juckett, Mark, additional, Bachanova, Veronika, additional, Weisdorf, Daniel J., additional, Ramesh, Vidhyalakshmi, additional, Arora, Mukta, additional, and Jurdi, Najla El, additional

Published
2024
Full Text
View/download PDF

31. Efficacy of Siltuximab for Chimeric Antigen Receptor T-Cell Therapy Toxicities – a Multicenter Retrospective Analysis

Author

Bajwa, Amneet, primary, Zhao, Qiuhong, additional, Geer, Marcus J., additional, Mian, Agrima, additional, Lin, Chenyu, additional, Frame, David, additional, Westholder, James, additional, Tossey, Dr. Justin, additional, Ghosh, Monalisa, additional, Galal, Ahmed, additional, Ahmed, Nausheen, additional, Maakaron, Joseph E., additional, Denlinger, Nathan, additional, de Lima, Marcos, additional, Epperla, Narendranath, additional, Caimi, Paolo, additional, and Voorhees, Timothy, additional

Published
2024
Full Text
View/download PDF

33. Patients with TP53 -Mutated Acute Myeloid Leukemia Receiving Intensive Induction Therapy Have Superior Outcomes Due to a Higher Rate of Salvage Therapy: A Single Institution, Retrospective Study.

Author

Sumransub, Nuttavut, Steinwand, Gabriel K., Cordner, Keith, Lee, Yoonkyu, Cao, Qing, Allred, Jeremy, Bachanova, Veronika, Juckett, Mark, Eckfeldt, Craig, Maakaron, Joseph E., Tracy, Sean I., Ramesh, Vidhyalakshmi, Nelson, Andrew C., Yohe, Sophia, and Sachs, Zohar

Subjects
THERAPEUTIC use of antineoplastic agents, RESEARCH funding, SALVAGE therapy, PATHOLOGIC complete response, TREATMENT effectiveness, RETROSPECTIVE studies, CANCER patients, DISEASE remission, DESCRIPTIVE statistics, TUMOR suppressor genes, ONCOGENES, MEDICAL records, ACQUISITION of data, GENETIC mutation, INDUCTION chemotherapy, OVERALL survival, EVALUATION
Abstract

Simple Summary: Mutations in the gene, TP53, define the most treatment-resistant subtype of acute myeloid leukemia (AML). Patients with TP53-mutated AML invariably develop disease recurrence after treatment, leading to short survival times. Previous studies have shown that less than 10% of these patients survive beyond 2 years after diagnosis. Moreover, the best treatment approach for these patients is still unclear. Our study is the first to analyze therapy results beyond first-line treatment, highlighting the importance of therapy sequencing in managing these patients. We found that sequential treatment with intensive chemotherapy followed by a less-intensive regimen achieved the highest remission rate of over 65%. Eligible patients should then receive blood stem cell transplantation from a donor, which significantly improves long-term survival. Our study provides crucial data to guide management and optimize therapy sequencing for better survival in this treatment-resistant disease. Background: TP53 mutations (TP53m) define the most treatment-refractory acute myeloid leukemia (AML) subtype. Optimal treatment approaches have not been established in this setting. We reviewed our institutional experience to identify therapy sequencing, treatment response, and survival patterns in these patients. Methods: This study was a single-center, retrospective cohort analysis. Results: Our cohort includes 86 TP53m and 337 TP53 wild-type (TP53wt) adult AML patients. TP53m AML patients presented with lower bone marrow and peripheral blasts; none presented with hyperleukocytosis. Patients who received intensive treatment up front demonstrated superior overall survival (OS) over those receiving first-line non-intensive therapy (2-year OS 22% versus 7%; p = 0.02). However, the complete remission (CR) rates among the first-line intensive and non-intensive therapy groups were comparable (21.9% and 29.4%, respectively, p = 0.49). The improved OS is therefore attributed to superior cumulative CR in the intensive group. First-line intensively treated patients were more likely to receive and respond to salvage, leading to a cumulative CR rate of 65.7% (versus 29.4%, p = 0.003). Achieving CR at any point is strongly associated with superior survival outcomes with 2-year OS of 31% versus 0% for those not achieving CR ever (p < 0.01). Conclusions: We find that TP53m AML rarely presents with oncological emergencies, suggesting that clinical trial enrollment is feasible in this group. Additionally, in our cohort, intensive induction therapies lead to superior survival outcomes attributed to successful salvage therapy. These data suggest that strategic therapy sequencing and salvage therapy may be important in optimizing outcomes for TP53m AML patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single‐Center Experience.

Author

Matar, Abraham J., Finger, Erik B., Maakaron, Joseph, Minja, Emmanuel, Ramanathan, Karthik, Humphreville, Vanessa, Rao, Joseph S., Fisher, Jessica, Sutherland, David E. R., Matas, Arthur J., and Kandaswamy, Raja

Subjects
PANCREAS transplantation, KIDNEY transplantation, LYMPHOPROLIFERATIVE disorders, PANCREATIC diseases, DISEASE risk factors
Abstract

Background: Chronic immunosuppression following pancreas transplantation carries significant risk, including posttransplant lymphoproliferative disease (PTLD). We sought to define the incidence, risk factors, and long‐term outcomes of PTLD following pancreas transplantation at a single center. Methods: All adult pancreas transplants between February 1, 1983 and December 31, 2023 at the University of Minnesota were reviewed, including pancreas transplant alone (PTA), simultaneous pancreas–kidney transplants (SPK), and pancreas after kidney transplants (PAK). Results: Among 2353 transplants, 110 cases of PTLD were identified, with an overall incidence of 4.8%. 17.3% were diagnosed within 1 year of transplant, 32.7% were diagnosed within 5 years, and 74 (67.3%) were diagnosed after 5 years. The overall 30‐year incidence of PTLD did not differ by transplant type—7.4% for PTA, 14.2% for SPK, and 19.4% for PAK (p = 0.3). In multivariable analyses, older age and Epstein‐Barr virus seronegativity were risk factors for PTLD, and PTLD was a risk factor for patient death. PTLD‐specific mortality was 32.7%, although recipients with PTLD had similar median posttransplant survival compared to those without PTLD (14.9 year vs. 15.6 year, p = 0.9). Conclusions: PTLD following pancreas transplantation is associated with significant mortality. Although the incidence of PTLD has decreased over time, a high index of suspicion for PTLD following PTx should remain in EBV‐negative recipients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

Author

El Jurdi, Najla, Elhusseini, Heba, Beckman, Joan, DeFor, Todd E., Okoev, Grigori, Rogosheske, John, Lazaryan, Aleksandr, Weiler, Kristen, Bachanova, Veronika, Betts, Brian C., Blazar, Bruce R., Brunstein, Claudio G., He, Fiona, Holtan, Shernan G., Janakiram, Murali, Gangaraju, Radhika, Maakaron, Joseph, MacMillan, Margaret L., Rashidi, Armin, Warlick, Erica D., Bhatia, Smita, Vercellotti, Gregory, Weisdorf, Daniel J., and Arora, Mukta

Published
2021
Full Text
View/download PDF

37. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

38. Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez Jimenez, Antonio M., De Lima, Marcos, Komanduri, Krishna V., Wang, Trent P., Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R., Hildebrandt, Gerhard C., Hogan, William J., Kanakry, Christopher G., Kansagra, Ankit, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Krem, Maxwell M., Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V., Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S., Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F., Wirk, Baldeep, Yared, Jean A., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, and Weisdorf, Daniel

Published
2022
Full Text
View/download PDF

39. Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL

Author

Scordo, Michael, primary, Flynn, Jessica R., additional, Gonen, Mithat, additional, Devlin, Sean M., additional, Parascondola, Allison, additional, Alarcon Tomas, Ana, additional, Shouval, Roni, additional, Brower, Jamie, additional, Porter, David L., additional, Schuster, Stephen J., additional, Bachanova, Veronika, additional, Maakaron, Joseph, additional, Maziarz, Richard T, additional, Chen, Andy I, additional, Nastoupil, Loretta J, additional, McGuirk, Joseph P, additional, Oluwole, Olalekan O., additional, Ip, Andrew, additional, Leslie, Lori A., additional, Bishop, Michael R., additional, Riedell, Peter A., additional, and Perales, Miguel-Angel, additional

Published
2023
Full Text
View/download PDF

40. Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma

Author

Cichocki, Frank, primary, Zhang, Bin, additional, Wu, Cheng-Ying, additional, Chiu, Emily, additional, Day, Abderrahman, additional, O’Connor, Roddy S., additional, Yackoubov, Dima, additional, Simantov, Ronit, additional, McKenna, David H., additional, Cao, Qing, additional, Defor, Todd E., additional, Janakiram, Murali, additional, Wangen, Rose, additional, Cayci, Zuzan, additional, Snyder, Nathaniel, additional, Kumar, Akhilesh, additional, Grzywacz, Bartosz, additional, Hwang, Justin, additional, Geffen, Yona, additional, Miller, Jeffrey S., additional, Maakaron, Joseph, additional, and Bachanova, Veronika, additional

Published
2023
Full Text
View/download PDF

42. Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Author

Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., Shouse, Geoffrey, Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Xiao-Wei Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish, Oh, Timothy S., Karmali, Reem, Kim, Seo-Hyun, Kress, Anna, Kothari, Shalin, Sawalha, Yazeed, Christian, Beth, David, Kevin A., Greenwell, Irl Brian, Janakiram, Murali, Kenkre, Vaishalee P., Olszewski, Adam J., Cohen, Jonathon B., Palmisiano, Neil, Umyarova, Elvira, Wilcox, Ryan A., Awan, Farrukh T., Alderuccio, Juan Pablo, Barta, Stefan K., Grover, Natalie S., Ghosh, Nilanjan, Bartlett, Nancy L., Herrera, Alex F., and Shouse, Geoffrey

Published
2023

43. Supplementary Figure S2 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Author

Holtan, Shernan G., primary, Savid-Frontera, Constanza, primary, Walton, Kelly, primary, Eaton, Anne A., primary, Demorest, Connor, primary, Hoeschen, Andrea, primary, Zhang, Ling, primary, Reid, Kayla, primary, Kurian, Tony, primary, Sayegh, Zena, primary, Julia, Estefania, primary, Maakaron, Joseph, primary, Bachanova, Veronika, primary, Jurdi, Najla El, primary, MacMillan, Margaret L., primary, Weisdorf, Daniel J., primary, Felices, Martin, primary, Miller, Jeffrey S., primary, Blazar, Bruce R., primary, Davila, Marco L., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table S1 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality

Author

Holtan, Shernan G., primary, Savid-Frontera, Constanza, primary, Walton, Kelly, primary, Eaton, Anne A., primary, Demorest, Connor, primary, Hoeschen, Andrea, primary, Zhang, Ling, primary, Reid, Kayla, primary, Kurian, Tony, primary, Sayegh, Zena, primary, Julia, Estefania, primary, Maakaron, Joseph, primary, Bachanova, Veronika, primary, Jurdi, Najla El, primary, MacMillan, Margaret L., primary, Weisdorf, Daniel J., primary, Felices, Martin, primary, Miller, Jeffrey S., primary, Blazar, Bruce R., primary, Davila, Marco L., primary, and Betts, Brian C., primary

Published
2023
Full Text
View/download PDF

45. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Author

Jurdi, Najla El, primary, Hoover, Alex, additional, O’Leary, Daniel, additional, Cao, Qing, additional, Gupta, Ashish, additional, Ebens, Christen, additional, Maakaron, Joseph, additional, Betts, Brian C., additional, Rashidi, Armin, additional, Juckett, Mark, additional, Lund, Troy, additional, Bachanova, Veronika, additional, MacMillan, Margaret, additional, Miller, Jeffrey, additional, Orchard, Paul, additional, Wagner, John, additional, Vercellotti, Gregory, additional, Weisdorf, Daniel, additional, Dusenbery, Kathryn, additional, Terezakis, Stephanie, additional, and Holtan, Shernan, additional

Published
2023
Full Text
View/download PDF

46. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Author

Jurdi, Najla El, Hoover, Alex, O’Leary, Daniel, Cao, Qing, Gupta, Ashish, Ebens, Christen, Maakaron, Joseph, Betts, Brian C., Rashidi, Armin, Juckett, Mark, Lund, Troy, Bachanova, Veronika, MacMillan, Margaret, Miller, Jeffrey, Orchard, Paul, Wagner, John, Vercellotti, Gregory, Weisdorf, Daniel, Dusenbery, Kathryn, Terezakis, Stephanie, and Holtan, Shernan

Subjects
Article
Abstract

IntroductionGraft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac) and mycophenolate mofetil (MMF) would reduce the incidence of GVHD in patients receiving a matched or single antigen mismatched HCT without an increase in risk of malignant relapse.MethodsThis is a phase II study conducted at the University of Minnesota using a myeloablative regimen of either: (A) total body irradiation (TBI, total dose 1320 cGy, administered in 165 cGy fractions, twice a day from days -4 to -1) or (B) Busulfan 3.2mg/kg daily (cumulative AUC 19,000 – 21,000 μmol/min/L) plus fludarabine 160mg/m2days -5 to -2, followed by a GVHD prophylaxis regimen of PTCy (50mg/kg days +3 and +4), Tac and MMF (beginning day +5). The primary endpoint is cumulative incidence of chronic GVHD requiring systemic immunosuppression at 1-year post-transplant. We compared results to our previous myeloablative protocol for matched donors utilizing cyclosporine/methotrexate (CSA/MTX) GVHD prophylaxis.ResultsFrom March 2018 - June 2022, we enrolled and treated 125 pediatric and adult patients with a median follow up of 472 days. Grade II-IV acute GVHD occurred in 16% (95% confidence interval (CI): 9-23%); Grade III-IV acute GVHD was 4% (CI: 0-8%). No patients experienced grade IV GVHD, and there were no deaths due to GVHD before day 100. Only 3 developed chronic GVHD requiring immune suppression, (4%, CI: 0-8%). Two-year overall survival (OS) was 80% (CI: 69-87%), and (graft-versus-host disease-free, relapse-free survival) GRFS 57% (CI: 45-67%), both higher than historical CSA/MTX. The incidence of grade II-IV aGVHD, cGVHD, and NRM were all lower with PTCy/Tac/MMF compared to historical CSA/MTX. One-quarter (25%) experienced relapse (CI: 15-36%) similar to historical CSA/MTX. There was no statistically significant difference in survival outcomes between recipients of matched versus 7/8 donors.ConclusionMyeloablative HCT with PTCy/Tac/MMF results in extremely low incidence of severe acute or chronic GVHD, the primary endpoint of this clinical trial. Relapse risk is not increased compared to our historical CSA/MTX cohort.

Published
2023
Full Text
View/download PDF

48. Cryopreservation for Allogeneic Hematopoetic Stem Cell Transplants Is Non-Inferior to Fresh Graft Products

Author

O’Leary, Daniel, primary, Goyal, Amrita, additional, Cao, Qing, additional, Maakaron, Joseph E., additional, Holtan, Shernan Grace, additional, Betts, Brian C., additional, Jurdi, Najla El, additional, McKenna, David H., additional, Zorko, Nicholas, additional, Kao, Roy, additional, MacMillan, Margaret L., additional, Bachanova, Veronika, additional, Weisdorf, Daniel J., additional, Miller, Jeffrey S., additional, and Juckett, Mark, additional

Published
2023
Full Text
View/download PDF

49. Nephrons and Non-Relapse Mortality (NRM): Simplified Comorbidity Index (SCI) and Acute Kidney Injury (AKI) Are Associated with NRM in Adults Undergoing Allogeneic Hematopoietic Cell Transplant

Author

Robinson, Clark Raymond, primary, Habib, Alma, additional, Klomjit, Nattawat, additional, Cao, Qing, additional, Kao, Roy, additional, Maakaron, Joseph E., additional, Juckett, Mark, additional, Weisdorf, Daniel J., additional, Miller, Jeffrey S., additional, Betts, Brian C., additional, Jurdi, Najla El, additional, and Holtan, Shernan Grace, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results